The Illusion of Scale in India’s Health Budget

When India’s Union Budget 2026 announced that healthcare spending had crossed ₹1 lakh crore, the number immediately took over headlines and timelines. It sounds historic, and in purely nominal terms, it is. A roughly 10% year-on-year increase signals that healthcare is no longer an afterthought in fiscal conversations. But big numbers in isolation rarely tell the full story, especially in public policy, where scale and context matter far more than symbolism. Once the initial excitement settles, the obvious question emerges: what does ₹1 lakh crore actually translate to in a country of nearly 1.4 billion people? The answer is sobering. Spread across the population, public healthcare spending comes to roughly ₹715 per person per year i.e. less than ₹2 a day. This is why, despite budget increases, India continues to spend only around 2% of its GDP on public healthcare, a figure well below global benchmarks and far behind most middle-income and developed economies. The headline sounds impressive, but the per-capita reality explains why households still shoulder much of the healthcare burden themselves.

This becomes clearer when we look at where the money is going. Large allocations continue for the National Health Mission and PM-JAY, India’s flagship schemes for primary care delivery and health insurance coverage. These programmes matter because they directly determine whether people can access basic services and avoid catastrophic medical expenses. Yet even here, the story is one of continuity rather than transformation. The budget strengthens existing structures but stops short of fundamentally altering how healthcare is financed or delivered at scale. The same pattern appears in the much-discussed focus on mental health. The budget does acknowledge the crisis by increasing allocations to mental health institutions and capacity-building, which is a necessary and overdue step. But India still has fewer than one psychiatrist per 100,000 people, well below the recommended benchmark of three or more. Without a massive expansion of the mental health workforce and integration of services into primary care, budgetary intent risks remaining largely symbolic. Recognition is important, but recognition alone does not close supply gaps.

Affordability is another recurring theme, particularly in the context of cancer care and high-cost treatments. The budget’s push for biopharma and biosimilars aims to reduce drug prices and strengthen domestic manufacturing, which could have long-term benefits. This matters because nearly half of India’s total health expenditure still comes directly from people’s pockets, and medicines form a major share of that spending. However, cheaper production does not automatically translate into cheaper access unless procurement, pricing, and insurance mechanisms are aligned. Drug affordability is as much a financing issue as it is an industrial one.

At the same time, the budget continues to prioritise visible investments in tertiary care. The ₹5,500 crore allocation to AIIMS Delhi is a clear example. World-class institutions are necessary, politically attractive, and undeniably valuable. But global evidence consistently shows that the highest health returns come from strong primary care systems, not from an ever-expanding network of specialised hospitals. When primary care is weak, tertiary hospitals become overcrowded, costs rise, and preventable conditions are treated far too late. The budget reflects this familiar trade-off between visibility and value.

Taken together, these choices point to a deeper structural issue. Despite incremental increases, India’s healthcare system remains constrained by low public spending, high out-of-pocket costs, and fragmented delivery across states and providers. Budgets can signal intent, but outcomes are shaped by sustained investment and systemic reform. Without a faster expansion of public health financing and stronger purchasing power by the state, headline numbers will continue to outpace real-world impact.